NLS Pharmaceutics AG (NASDAQ:NLSP) Short Interest Down 55.2% in September

NLS Pharmaceutics AG (NASDAQ:NLSP) was the recipient of a significant drop in short interest in the month of September. As of September 30th, there was short interest totalling 48,900 shares, a drop of 55.2% from the September 15th total of 109,200 shares. Currently, 0.8% of the shares of the company are sold short. Based on an average daily volume of 467,800 shares, the short-interest ratio is presently 0.1 days.

A number of large investors have recently modified their holdings of NLSP. Citadel Advisors LLC bought a new position in NLS Pharmaceutics in the second quarter worth about $33,000. Millennium Management LLC bought a new stake in shares of NLS Pharmaceutics during the first quarter valued at approximately $134,000. Renaissance Technologies LLC bought a new stake in NLS Pharmaceutics during the 2nd quarter valued at $132,000. Finally, Axiom Investment Management LLC bought a new position in shares of NLS Pharmaceutics in the first quarter worth $273,000. 0.55% of the stock is owned by institutional investors.

NLSP stock traded up $0.16 during trading on Thursday, reaching $2.56. 59,003 shares of the stock traded hands, compared to its average volume of 1,371,385. The firm has a market capitalization of $30.15 million and a PE ratio of -6.24. The business’s 50 day moving average price is $2.52 and its 200-day moving average price is $3.02. NLS Pharmaceutics has a 52-week low of $2.06 and a 52-week high of $7.35.

Separately, Zacks Investment Research raised shares of NLS Pharmaceutics from a “sell” rating to a “hold” rating in a report on Wednesday, September 15th.

NLS Pharmaceutics Company Profile

NLS Pharmaceutics AG, a biopharmaceutical company, engages in the discovery and development of drug therapies to treat rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD).

See Also: The Role of a Fiduciary and Individual Investors

Receive News & Ratings for NLS Pharmaceutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NLS Pharmaceutics and related companies with's FREE daily email newsletter.